Lrrk2 inhibitors - Articles - Page 2

Neurology/psychiatric

DM Intelligence Medicine patents new LRRK2 and EGFR inhibitors

Dec. 23, 2024

DM Intelligence Medicine Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin), LRRK2 (G2019S mutant) and/or EGFR (HER1; erbB1 mutant) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.

Neurology/psychiatric

Shanghai Institute of Organic Chemistry discovers new LRRK2 inhibitors

Dec. 17, 2024

Shanghai Institute of Organic Chemistry has described leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory disorders, Parkinson’s disease and Alzheimer’s disease, among others.

Neurology/psychiatric

Vanderbilt University describes new LRRK2 inhibitors

Sep. 20, 2024

Vanderbilt University has identified leucine-rich repeat kinase 2 (LRRK2; dardarin) and LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of tauopathies, cancer, Crohn’s disease, type 1 diabetes, leprosy, rheumatoid arthritis, traumatic brain injury and Alzheimer’s disease, among others.

Seed and series As down but not out: Brenig, Third Arc at bat

July 23, 2024

By Karen Carey

After reaching a height in 2021, seed and series A rounds have fallen in recent years, and 2024 is no exception, although amounts raised are tracking slightly ahead of last year. On July 23, the numbers were given a boost when two new companies – namely Dover, Del.-based Brenig Therapeutics Inc. and Boston-based Third Arc Bio Inc. – raised $65 million and $165 million, respectively, in series A financings. A third new company, Abiologics Inc., also received $50 million in initial funding.

Neurology/psychiatric

Neuron23 describes new LRRK2 inhibitors for Parkinson’s disease

June 12, 2024

Neuron23 Inc. has synthesized leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Neurology/Psychiatric

Lundbeck and Vernalis present new LRRK2 and LRRK2 G2019S mutant inhibitors

April 11, 2024

Scientists at H. Lundbeck A/S and Vernalis (R&D) Ltd. have divulged leucine-rich repeat kinase 2 (LRRK2; Dardarin) and LRRK2 G2019S mutant inhibitors reported to be useful for the treatment of Parkinson’s disease, Lewy body dementia and multiple system atrophy.

Neurology/Psychiatric

Neuron23 divulges new LRRK2 inhibitors

April 4, 2024

Neuron23 Inc. has synthesized leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, neurodegeneration and Parkinson’s disease.

Cancer

Deciphera Pharmaceuticals discovers new ULK and LRRK2 inhibitors

March 28, 2024

Deciphera Pharmaceuticals LLC has described serine/threonine-protein kinase ULK1 and/or ULK2 and/or leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.

Elderly woman holding illustration of brain with missing puzzle piece

Neurology/Psychiatric

BT-0267, a highly selective and orally bioavailable LRRK2 inhibitor for PD

March 25, 2024

Leucine-rich repeat kinase 2 (LRRK2), a key drug target, plays a major role in Parkinson’s disease (PD). Mutations in LRRK2, specifically LRRK2 G2019S which increases LRRK2 kinase activity, have been observed in a majority of PD patients.